- BioDuro has entered a strategic partnership with CTI Biotechnology to provide integrated preclinical R&D services from drug discovery through IND submission.
- The collaboration combines BioDuro’s discovery and manufacturing capabilities with CTI’s GLP toxicology and bioanalytical services.
BioDuro announced a strategic partnership with CTI Biotechnology (Suzhou) Co., Ltd. to establish an integrated platform supporting drug discovery through investigational new drug (IND) submission. The collaboration is designed to provide biotech and pharmaceutical companies with coordinated preclinical development services.
Under the agreement, BioDuro will deliver capabilities across discovery chemistry, biology, drug metabolism and pharmacokinetics (DMPK), pharmacology, as well as API and drug product development and contract manufacturing. The company will also support IND filings across global markets. CTI Biotechnology will contribute GLP toxicology studies and bioanalytical services to support regulatory submissions.
The partnership aims to combine the expertise of both companies to streamline project execution and reduce operational complexity for clients. By integrating services across multiple stages of preclinical development, the companies intend to support more efficient progression of drug candidates.
“Successful IND submission depends on strong execution across every critical step of early development, and GLP toxicology is one of the most important milestones in that journey. The collaboration strengthens BioDuro’s ability to support clients in advancing programs with greater efficiency.”
Armin Spura, Ph.D., CEO of BioDuro
CTI Biotechnology stated that the collaboration will enhance its service capabilities in preclinical development and provide clients with a more comprehensive solution. The companies plan to work together to support global R&D programs and facilitate the development of new therapies.
